EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?

Faustman, Denise L.

doi:10.1586/eci.12.101

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TNF is known to protect the host through autoreactive T cell death [7] and also induction of Tregs [24][25][26]. Our observational study and previous studies [6,27] extend the epidemiologically-driven "hygiene hypothesis" by demonstrating that EBV infection or deliberate reintroduction of attenuated tuberculosis bacteria results in amelioration of autoimmunity even years after disease onset.…”

Section: Discussionsupporting

confidence: 71%

Possible Transient Benefits of Epstein Barr Virus Infection in Three Subjects with Established Type 1 Diabetes

Leung¹

2014

J Diabetes Metab

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 71%

Possible Transient Benefits of Epstein Barr Virus Infection in Three Subjects with Established Type 1 Diabetes

Leung¹

2014

J Diabetes Metab

View full text Add to dashboard Cite

“…Therefore, in the following decades, much time was spent in defining potential immune therapies that would be more ‘palatable’ for patients in terms of side effects – monoclonal antibodies against CD3 being the most notable advance[7]. However, over the years of testing in recently diagnosed patients, prevention of C-peptide decline has proven heterogeneous and often associated with reactivation of EBV when effective[8]. Thus, the efficacy to side effect balance remains a rather tenuous one, and the hope that the 1970s and 80s offered has not translated into a therapy nearly 50 years later.…”

mentioning

confidence: 99%

The shifting paradigm of a “cure” for type 1 diabetes: is technology replacing immune-based therapies?

Pettus

Herrath

2017

Acta Diabetol

View full text Add to dashboard Cite

Nearly 50 years after the autoimmune nature of type 1 diabetes was discovered, no therapy has been approved to alter the course of the disease at any stage. However, during that same period, technology has been delivering tools to help patients achieve better glycemic control and reduce the burden of the disease. With the imminent arrival of fully automated artificial pancreas systems that will continue to improve control and quality of life, it appears that we are on the verge of a major technological breakthrough that will significantly impact diabetes care. These devices have such a high degree of potential that they are, at times, mentioned as a virtual cure for the disease-a first for technology in this space. As such, these devices will undoubtedly alter the research landscape in a field that has predominantly been occupied by immunotherapies. This article reviews the history of type 1 diabetes and compares and contrasts the advancements that have come from the world of technology and immunology alike at this important crossroads in care that we are currently in.

show abstract

Epstein-Barr virus infection as a predisposing factor for multiple sclerosis. An update from molecular biology, immunology and epidemiology

et al. 2019

View full text Add to dashboard Cite

Introduction: Epstein-Barr virus is an infectious agent used to immortalize and induce polyclonal activation of B cells. It has been widely described that this virus produces changes in the cells it infects and in the immune response, and stimulates the development of autoimmune diseases.Objective: To characterize the association between Epstein-Barr virus and multiple sclerosis described in current scientific literature.Materials and methods: A 59-years range literature search was conducted in the PubMed, ScienceDirect, Redalyc and SciELO databases using the following MeSH terms: “Epstein-Barr virus, multiple sclerosis autoimmune diseases, autoimmune diseases of the nervous system”.Results: Many studies describe the association between Epstein-Barr virus and multiple sclerosis. It is believed that acute infection and viral reactivation promote the development of multiple sclerosis.Conclusions: It is necessary to conduct further research on the pathogenesis and morphophysiological and neuroimmunological changes –at the ecological, molecular, cellular, tissue, organic and systemic level– induced by the immune response and that favor the development of multiple sclerosis.

show abstract

EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?

Cited by 3 publications

References 18 publications

Possible Transient Benefits of Epstein Barr Virus Infection in Three Subjects with Established Type 1 Diabetes

Possible Transient Benefits of Epstein Barr Virus Infection in Three Subjects with Established Type 1 Diabetes

The shifting paradigm of a “cure” for type 1 diabetes: is technology replacing immune-based therapies?

Epstein-Barr virus infection as a predisposing factor for multiple sclerosis. An update from molecular biology, immunology and epidemiology

Contact Info

Product

Resources

About